Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Non-Current Liabilities (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $2.9 million as the latest value for Q2 2023.

  • Quarterly Total Non-Current Liabilities fell 73.0% to $2.9 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Jun 2023, down 73.0% year-over-year, with the annual reading at $7.0 million for FY2022, 37.42% down from the prior year.
  • Total Non-Current Liabilities for Q2 2023 was $2.9 million at Marker Therapeutics, down from $6.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $11.9 million in Q3 2020, with the low at $226111.0 in Q1 2020.
  • Average Total Non-Current Liabilities over 5 years is $7.0 million, with a median of $8.1 million recorded in 2020.
  • The sharpest move saw Total Non-Current Liabilities soared 5083.22% in 2021, then plummeted 73.0% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $280247.0 in 2019, then surged by 4134.99% to $11.9 million in 2020, then dropped by 5.23% to $11.2 million in 2021, then plummeted by 37.42% to $7.0 million in 2022, then tumbled by 58.51% to $2.9 million in 2023.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $2.9 million, $6.8 million, and $7.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.